Evaluation of Association between Tumor Markers, Hormonal Receptors, Inflammatory Biomarkers and Breast Cancer Biomarkers in Breast Cancer
Abstract
Background: Male breast cancer, though rare, requires reliable diagnostic and prognostic markers. This study evaluated tumor markers, hormonal receptors, and inflammatory biomarkers in male breast cancer.
Methods: A case–control study included 150 men with breast cancer and 50 matched controls (38–52 years). Diagnosis was confirmed by clinical evaluation, mammography, and histopathology. Serum was collected and stored at −80°C. Tumor markers—cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) and inflammatory biomarkers, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) were measured using enzyme-linked immunosorbent assay (ELISA). Hormonal receptors, estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR) were measured by Cobas e411 immunoassay.
Results: Age and education were similar between groups. Patients had higher smoking rates (45% vs. 20%, p = 0.01) and body mass index (28.6 ± 3.2 vs. 26.1 ± 2.8 kg/m², p = 0.02). Tumor markers, hormonal receptors, and inflammatory biomarkers were significantly elevated in patients (p < 0.001). Strong correlations were found between CA15-3 and IL-6 (r = 0.68), ER and CRP (r = 0.55), and PR and TNF-α (r = 0.61).
Conclusions: Elevated tumor markers, hormonal receptors, and inflammatory biomarkers indicate a link between inflammation, hormonal regulation, and tumor progression, highlighting their diagnostic and prognostic value in male breast cancer.
Full text article
References
Burstein, H.J.; Mangu, P.B.; Somerfield, M.R.; Schrag, D.; Samson, D.; Holt, L.; Zelman, D.; Ajani, J.A. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 2011, 29, 3328–3330. https://doi.org/10.1200/JCO.2011.36.0354.
Carlson, R.W.; Allred, D.C.; Anderson, B.O.; et al. Invasive breast cancer. J. Natl. Compr. Cancer Netw. 2011, 9, 136–222. https://doi.org/10.6004/jnccn.2011.0016.
Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781–791. https://doi.org/10.1056/NEJMoa040766.
Garreffa, E.; Arora, D. Breast cancer in the elderly, in men and during pregnancy. Surgery 2022, 40, 139–146. https://doi.org/10.1016/j.mpsur.2024.09.004.
Abdelwahab Yousef, A.J. Male Breast Cancer: Epidemiology and Risk Factors. Semin. Oncol. 2017, 44, 267–272. https://doi.org/10.1053/j.seminoncol.2017.11.002.
Avau, F.; Chintinne, M.; Baudry, S.; Buxant, F. Literature review and case report of bilateral intracystic papillary carcinoma associated with an invasive ductal carcinoma in a male breast. Breast Dis. 2022, 41, 5–13. https://doi.org/10.3233/BD-210001.
Allegra, C.J.; Jessup, J.M.; Somerfield, M.R.; et al. ASCO provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma. J. Clin. Oncol. 2009, 27, 2091–2096. https://doi.org/10.1200/JCO.2009.21.9170.
Gradishar, W.J.; Moran, M.S.; Abraham, J.; et al. NCCN Guidelines Insights: Breast Cancer, Version 4.2021. J. Natl. Compr. Canc. Netw. 2021, 19, 484–493. https://doi.org/10.3390/curroncol30020139.
Guidelinesprogramm Onkologie. Interdisciplinary S3-Guidelines... AWMF. Accessed 11 Feb 2023. https://doi.org/10.3390/cancers16173049.
Seale, K.N.; Tkaczuk, K.H.R. Circulating Biomarkers in Breast Cancer. Clin. Breast Cancer 2022, 22, e319–e331. https://doi.org/10.1016/j.clbc.2021.09.006.
Luo, J.; Xiao, J.; Yang, Y.; et al. Strategies for five tumour markers in breast cancer diagnosis. Front. Oncol. 2023, 12, 1055855. https://doi.org/10.3389/fonc.2022.1055855.
Goldhirsch, A.; Wood, W.C.; Coates, A.S.; et al. Strategies for subtypes – Highlights of the St. Gallen 2011. Ann. Oncol. 2011, 22, 1736–1747. https://doi.org/10.1093/annonc/mdr304.
Hanif, H.; Ali, M.J.; Susheela, A.T.; et al. Update on alpha-fetoprotein for HCC. World J. Gastroenterol. 2022, 28, 216–229. https://doi.org/10.3748/wjg.v28.i2.216.
Desplat-Jégo, S.; Burkly, L.; Putterman, C. Targeting TNF and family in autoimmune diseases. Mediators Inflamm. 2014, 2014, 628748. https://doi.org/10.1155/2014/628748.
Alfano, C.M.; Peng, J.; Andridge, R.R.; et al. Inflammatory cytokines and comorbidities in breast cancer survivors. J. Clin. Oncol. 2017, 35, 149–156. https://doi.org/10.1200/JCO.2016.67.1883.
Bachelot, T.; Ray-Coquard, I.; Menetrier-Caux, C.; et al. Prognostic value of IL-6 in breast cancer. Br. J. Cancer 2003, 88, 1721–1726. https://doi.org/10.1038/sj.bjc.6600956.
Birbo, B.; Madu, E.E.; Madu, C.O.; et al. Role of HSP90 in Cancer. Int. J. Mol. Sci. 2021, 22, 10317. https://doi.org/10.3390/ijms221910317.
Cheng, Q.; Chang, J.T.; Geradts, J.; et al. HSP90 expression in HER2-negative breast cancer. Breast Cancer Res. 2012, 14, R62. https://doi.org/10.1186/bcr3168.
Pick, E.; Kluger, Y.; Giltnane, J.M.; et al. High HSP90 expression linked to poor survival. Cancer Res. 2007, 67, 2932–2937. https://doi.org/10.1158/0008-5472.CAN-06-4511.
Padron-Monedero, A.; et al. Smoking and survival in male breast cancer. Breast Cancer Res. Treat. 2015, 153, 679–687. https://doi.org/10.1007/s10549-015-3582-1.
Konishi, T.; et al. Short-term outcomes between men and women with breast cancer. Breast Cancer Res. Treat. 2021, 186, 731–739. https://doi.org/10.1007/s10549-020-06069-4.
Alsayer, R.M.; et al. Lifestyle risk factors for breast cancer in Saudi women. Breast Cancer: Targets Ther. 2024, 545–554. https://doi.org/10.2147/BCTT.S463193.
Fakhri, N.; et al. Risk factors for breast cancer in women: an updated review. Med. Oncol. 2022, 39(12), 197. https://doi.org/10.1007/s12032-022-01804-x.
Ryu, J.M.; et al. CA15-3 in early breast cancer. J. Breast Cancer 2023, 26(2), 126. https://doi.org/10.4048/jbc.2023.26.e17.
Zou, P.; et al. Prognostic value of CEA, CA153, HE4, and inflammation in breast cancer. Afr. Health Sci. 2024, 24(4), 224–232. https://doi.org/10.4314/ahs.v24i4.29.
Zhu, Z.; et al. AFP peptide and prostate cancer. Med. Oncol. 2022, 39(1), 2. https://doi.org/10.1007/s12032-021-01598-4.
Khan, N.A.J.; Tirona, M. Review on male breast cancer. Med. Oncol. 2021, 38(4), 39. https://doi.org/10.1007/s12032-021-01486-x.
Reinisch, M.; et al. Endocrine therapy for male breast cancer: MALE trial. JAMA Oncol. 2021, 7(4), 565–572. https://doi.org/10.1001/jamaoncol.2020.7442.
Wang, X.; Liu, S.; Xue, Y. Prognosis of male breast cancer. J. Int. Med. Res. 2021, 49(10), 03000605211049977. https://doi.org/10.1177/03000605211049977.
Yardley, D.A.; et al. Orteronel in AR-expressing MBC. Clin. Breast Cancer 2022, 22(3), 269–278. https://doi.org/10.1016/j.clbc.2021.10.011.
Lin, A.P.; Huang, T.W.; Tam, K.W. Treatment of male breast cancer: Meta-analysis. Br. J. Surg. 2021, 108(9), 1034–1042. https://doi.org/10.1093/bjs/znab279.
Burstein, H.J.; et al. Endocrine and targeted therapy for HR+/HER2− metastatic breast cancer. J. Clin. Oncol. 2021, 39(35), 3959–3977. https://doi.org/10.1200/JCO.21.01392.
Tsoi, H.; et al. Targeting IL-6/STAT3 to reverse tamoxifen resistance. Cancers 2021, 13(7), 1511. https://doi.org/10.3390/cancers13071511.
Gu, Y.; et al. Inflammatory markers and CA199 in pancreatic cancer. BMC Cancer 2023, 23(1), 227. https://doi.org/10.1186/s12885-023-10653-4.
Romero-Elías, M.; et al. CRP and physical fitness in breast cancer survivors. J. Clin. Med. 2022, 12(1), 65. https://doi.org/10.3390/jcm12010065.
Parimelazhagan, R.; et al. [Retracted] Visfatin and cytokines in hypertension. Biomed. Res. Int. 2021, 2021, 8568926. https://doi.org/10.1155/2024/9820645.
Powell, I.J.; et al. Pro-inflammatory cytokines in prostate cancer and racial disparity. Urol. Oncol. 2021, 39(1). https://doi.org/10.1016/j.urolonc.2020.08.019.
Tarighati, E.; Keivan, H.; Mahani, H. Review of biomarkers in breast cancer. Clin. Exp. Med. 2023, 23(1), 1–16. https://doi.org/10.1007/s10238-021-00781-1.
Cairat, M.; et al. Inflammatory biomarkers and breast cancer risk. BMC Med. 2022, 20(1), 118. https://doi.org/10.1186/s12916-022-02319-y.
Hussain, A.M.; Ali, A.H.; Mohammed, H.L. Correlation between serum and tissue markers in breast cancer Iraqi patients. Baghdad Sci. J. 2022, 19(3), 0501–0501.
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.